NexImmune, Inc.
NEXI · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | 89.2% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -241.9% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -252.7% | – |
| EPS Diluted | -1.69 | -2.46 | -5.03 | -9.4 |
| % Growth | 31.3% | 51.1% | 46.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |